Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05860075
Other study ID # IMM01-I
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date November 19, 2019
Est. completion date October 26, 2022

Study information

Verified date April 2023
Source ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM01 in subjects with refractory or recurrent hematologic malignancy.


Description:

IMM01 is administered via intravenous infusion once week of cycle 1- 12 (4 weeks per cycle). The accelerated titration method and the traditional "3+3" method will be adopted to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) in dose-escalation phase. Once the RP2D is determined, will explore for Classic Hodgkin's lymphoma, B-cell lymphoma,NK/T-cell lymphoma, AML, MDS and MM cohorts.


Recruitment information / eligibility

Status Terminated
Enrollment 73
Est. completion date October 26, 2022
Est. primary completion date October 26, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. They are voluntary to sign an informed consent form, agree to follow and have the ability to complete all trial procedures with knowledge of the study; 2. Male or female, aged =18 and = 75 years; 3. Patients with refractory or recurrent lymphoma diagnosed according to the 2016 WHO classification criteria; the relapsed, refractory lymphoma is defined as follows: Relapse is considered to occur when a new lesion appears at the primary site or elsewhere when response has been achieved with at least one current standard or commonly used regimen; Lymphoma is considered refractory if one of the following conditions is met: Less than 50% tumor shrinkage or disease progression occurs after =4 cycles of treatment with current standard or commonly used regimens; Patients who have achieved partial or complete response by current standard or commonly used regimens and relapsed within six months after termination of treatment; 4. There is at least one measurable or evaluable tumor lesion (preferentially enrolled the measurable lesions), measurable lesions: lymph nodes with longest diameterof =15 mm, metastatic lesions (=10 mm) at other sites; lesions previously treated with local therapy such as radiotherapy are considered measurable lesions if disease progression has been demonstrated; 5. Patients with a performance status score of 0~2 according to the Eastern Cooperative Oncology Group (ECOG) scale; 6. Expected life expectancy of at least 3 months; 7. If prior anti-tumor therapy has been received , the interval to the first dose in this study should meet the following conditions: Those who have used chemotherapy drugs previously need to discontinue for more than 4 weeks.Those with a history of surgery, targeted therapy (including anti CD20 monoclonal antibodies such as rituximab; CD30 monoclonal antibodies such as Brentuximab Vedotin), therapy with anti tumor indications, and palliative radiotherapy should discontinue the treatment for more than 4 weeks;Those with prior CAR-T cell therapy or PD-1/PD-L1 monoclonal antibody therapy need to discontinue for at least 8 weeks;And they have recovered from toxic reactions to previous treatment to grade = 1 identified by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (NCI CTCAE v5.0) (except for residual alopecia). 8. Suitable organs and hematopoietic functions are available. Absolute neutrophil count (ANC) =1.0×109/L (no use of short-acting leucopenia drugs within 1 week or no use of long-acting leucopenia drugs within 3 weeks). Patients have not received platelet transfusion within 1 week; platelets =75×109/L (without bone marrow infiltration)/ =50.0×109/L (with bone marrow infiltration). Patients have not received red blood cell transfusion within 2 weeks; hemoglobin =90 g/L (without bone marrow infiltration)/ =70 g/L (with bone marrow infiltration). Serum creatinine = 1.5 times the upper limit of normal (ULN). AST and ALT = 2.0 times ULN; Serum total bilirubin (TBIL) = 2 times ULN; International normalized ratio (INR) = 2 times ULN, or activated partial thromboplastin time (APPT) = 1.5 times ULN; 9. Male subjects and female subjects of childbearing age should agree to take effective contraceptive measures from the time they sign the informed consent until 6 months after the last dos Exclusion Criteria: 1. Patients with any of the following cannot be enrolled: previous allogeneic hematopoietic stem cell transplantation and other organ transplantation; a history of autologous hematopoietic stem cell transplantation for not more than six months. 2. Patients have participated in clinical trials of other drugs or medical devices within 4 weeks prior to the first dose of this study; 3. Presence of central nervous system metastatic lesion; 4. Patients with previous or current other malignancies (except cured stage IB or lower grade cervical cancer, non-invasive basal cell or squamous cell skin cancer; except other malignancies that have achieved complete response (CR) for >5 years and have not been treated with antineoplastic therapy for 5 years); 5. Subjects with active autoimmune disease, or a history of autoimmune disease with a risk of relapse (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis, etc., see Appendix 6), or patients at high risk (e.g., those requiring immunosuppressive therapy after undergoing organ transplantation). However, subjects with the following diseases are allowed to enroll : Those with autoimmune hypothyroidism who require hormone replacement therapy only; Those with skin conditions (such as eczema, rash covering less than 10% of the body's surface) that do not require systemic treatment; 6. Patients who have undergone major surgery within 28 d prior to enrollment or who are expected to have major surgery during this study period including the 21 d screening period. 7. Subjects requiring systemic corticosteroids (at a dose equivalent to >10 mg prednisone/d) or other immunosuppressive drugs within 14 d prior to enrollment or during the study period; the the patients meet the following conditions are allowed for enrollment: Subjects are allowed to use topical or inhaled glucocorticoids; Short-term (=7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases is allowed; 8. Patients with a history of arterial thrombosis or deep vein thrombosis within 6 months prior to enrollment or with evidence or history of bleeding tendency within 2 months prior to enrollment, regardless of severity; partial prothrombin time (APTT) or prothrombin time (PT) > 1.2 × ULN; oral warfarin with an international normalized ratio (INR) > 1.2 × ULN 9. Patients with acute lung disease, interstitial lung disease or pneumonia (except for local interstitial pneumonia induced by radiotherapy), pulmonary fibrosis, acute lung disease, etc.; 10. Systemic diseases that have not been stably controlled after treatment, such as diabetes, severe organic cardiovascular disease, cardiac insufficiency, hypertension, heart block of degree II or higher, myocardial infarction within 6 months and cerebral infarction within 6 months, etc; 11. Patients with positive HIV test; 12. Patients with active tuberculosis disease at screening; 13. Patients with HBsAg (+); with HBsAg (-) but HBV-DNA quantification exceeding the upper limit of the normal; Patients with HCV-Ab (+); with HCV-Ab (-) but HCV-RNA quantification exceeding the upper limit of the normal; 14. Patients with serious infections within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis or severe pneumonia. 15. Patients with uncontrolled active infectious lesions requiring oral or intravenous antibiotic therapy; 16. Subjects with a history of severe allergy or those who are known to have had severe allergic reactions to large molecular protein preparation/monoclonal antibodies, and any of the components of the investigational drug (greater than grade 3 according to NCI-CTCAE v5.0 classification); 17. Patients with a history of alcohol, drug or substance abuse within the last 1 year; 18. Patients with a clear previous history of neurological or psychiatric disorders with poor compliance, such as epilepsy, dementia; 19. Pregnant and lactating women; 20. Subjects with other conditions not suitable for participating in the study at the investigator's discretion

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IMM01
IMM01 will be administered once a week for 4 weeks.

Locations

Country Name City State
China Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events (AEs) and Serious Adverse Events (SAEs) Incidence and characteristics of adverse events (AEs), serious adverse events (SAEs) 48 weeks of treatment
Primary Dose-limiting toxicities (DLTs) Incidence and characteristics of dose-limiting toxicities (DLTs) Evaluated during the first treamtment cycle of 28 days
Primary Maximum Tolerated Dose(MTD ) MTD is the highest dose in patients with DLT incidence <30%. 48 weeks of treatment
Secondary Anti-drug antibody (ADA) To evaluate the immunogenicity of IMM01 in patients with refractory or recurrent hematologic malignancy 48 weeks of treatment
Secondary Overall Rate Response (ORR) ORR is defined as the proportion of participants who have a partial response (PR) or critical response (CR) When the last subject enrolled completes approximately 48 weeks of treatment
Secondary Disease Control Rate (DCR) DCR is defined as the proportion of participants who have a critical response (CR), partial response (PR) or disease stable (SD) From start of treatment to the last subject enrolled completes approximately 48 weeks of treatment]
Secondary Duration of Response (DOR) DOR is defined as time from date of initial documentation of a response (PR or CR) to date of first documented evidence of progressive disease (PD) From start of treatment to the last subject enrolled completes approximately 48 weeks of treatment
Secondary Progression-free survival (PFS) Defined as the duration from the start of treatment until tumor progression or death of any cause From start of treatment to treatment termination visit, up to 48 weeks
Secondary Maximum Plasma Concentration (Cmax) Maximum Plasma Concentration observed in patients with IMM01 dosed 48 weeks of treatment
Secondary time to maximum concentration (Tmax) time to maximum concentration observed in patients with IMM01 dosed 48 weeks of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04889937 - Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
Not yet recruiting NCT05820126 - Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial Phase 2
Active, not recruiting NCT04509765 - A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT N/A
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Withdrawn NCT03986086 - MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT02512666 - Non Invasive Optical Imaging of WBC Count N/A
Withdrawn NCT02207764 - Reiki as a Complementary Therapy: A Pilot Study N/A
Not yet recruiting NCT02193399 - Physiotherapy in Hematopoietic Stem Cell Transplantation N/A
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Terminated NCT01215981 - Influenza Vaccine Post Allogeneic Transplant N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Withdrawn NCT04392128 - Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) Phase 2
Recruiting NCT06102213 - Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation Phase 2
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Completed NCT03654404 - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients N/A
Recruiting NCT05384288 - Response to Influenza Vaccination in Pediatric Oncology Patients
Recruiting NCT05084027 - Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT Phase 2